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Abstract
The concept of immunological surveillance, a monitoring process in which the immune
system detects and destroys by several effector mechanisms, virally infected and neoplas-
tic transformed cells in the body, was developed more than 50 years ago. Based on current
research, it is clear that the immune system can recognize and eliminate transformed cells.
An increasing number of studies has investigated the immune system in cancer patients
and how it is prone to immunosuppression, due in part to the decrease of lymphocyte
proliferation and cytotoxic activity. Such weakened immune system is then unable to fully
accomplish its role in immunological surveillance, allowing nascent transformed cells to
escape the selective pressure of the immune system. The main goal of cancer immunother-
apy has been to reawaken the immune system from a suppressive slumber to enable it to
attack cancer cells once again. As the results from the last 10 years attest, cancer immuno-
therapy is the best strategy to restore the activity of the immune system and unleash its
potential to destroy cancer cells in cancer patients. This chapter aims to discuss the recent
findings on immune monitoring studies and the use of immune checkpoint inhibition in
cancer immunotherapy.
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1. Introduction
Throughout the evolutionary process, the immune system has developed mechanisms to
protect the living beings against infections by different microorganisms, viruses, and parasites.
A notorious question in immunology has been whether an immune response could also be
raised against transformed cells. Researchers have indeed, for a long time, studied if cancer
prevention could be a primary function of the immune system. The concept of immunological
surveillance, a monitoring process in which the immune system detects and destroys virally
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infected and neoplastic transformed cells, was elaborated more than 50 years ago by Lewis
Thomas and Sir Frank Macfarlane Burnet [14]. Back in history, William B. Coley in 1893, an
American bone surgeon and a pioneer in cancer immunotherapy, created a purified lysate of
multiple bacteria to treat a young patient who had developed an inoperable sarcoma. As a
result of the treatment, the patient had a complete remission. As head of the Bone Tumor
Service at Memorial Hospital in New York, Dr. Coley would still inject more than 1000 cancer
patients with bacterial products, then called Coleys toxins, which later were used by several
physicians in several patients with bone and soft tissue sarcomas, reporting some excellent
results [5]. In fact, the concoction initially called Coleys Toxin contained heat-killed Streptococ-
cus combined with live Serratia marcescens. To Dr. Coley, the infection that he produced could
contribute to shrinking malignant tumors. In 1909, the German biochemist Paul Ehrlich,
winner of the Nobel Prize in Physiology and Medicine and father of chemotherapy, introduced
the word Zauberkugel (the magic bullet) to describe antibodies. Generations of scientists
interpreted the magic bullet as a compound that would target a single critical oncoprotein [6].
Unfortunately, at that time, the pioneering work led by Coley and Ehrlich could not explain the
underlying mechanisms that activated the immune system to recognize and kill cancer cells.
Nowadays, their ideas and the early experiments, which were aimed at fighting cancer and
infectious diseases, serve to inspire new generations of researchers to develop compelling
strategies of targeted therapeutics and immunotherapy. However, the role of the immune
system in cancer recognition faced a shadowy period of disbelief mainly due to the difficulty
in reproducing tumor regression in different types of cancer using Coleys toxin [7], the
extremely toxic treatment [8], rejection of transplantable tumors [9], and the fact that thymic
selection removed autoreactive T cells. These shreds of evidence led the scientists to believe
that the role of the immune system as a primary strategy for recognizing cancer cells was
minimal. With the advent of studies on cellular and molecular biology after the 1980s, several
experiments were carried out to demonstrate that the immune system could efficiently act
against cancer initiation and development. The fact that autoreactive T cells can escape from
thymic selection [10], the discovery of tumor-associated antigensTAAs [11], tumor antigen
cross-presentation by dendritic cells to T lymphocytes [12], and the high frequency of cancer
development in immunodeficient mice (STAT/, IFN/, RAG/, TCRβ/, TCRδ/,
perforin/) [13] have considerably strengthened the concept of a protective immune system
in the last decades. Figure 1 displays a short chronological timeline of discoveries and pro-
gresses in cancer immunotherapy.
Hanahan and Weinberg on defining critical aspects of cancer development and progression,
described a set of biological capabilities defined as hallmarks of cancer. In their conceptual-
ization, there are eight hallmark capabilities that are common to many, if not most forms of
human cancer: sustained cell proliferation, evasion from growth suppressors, cell death resis-
tance, replicative immortality, angiogenesis, tissue invasion and metastasis, deregulation of
cellular energetics/metabolism, and avoidance of immune destruction [14, 15]. The primary
goal of cancer immunotherapy has been to reawaken the immune system from a suppressive
slumber to enable it to attack cancer cells once again. The fundamental principles that orches-
trate cancer immunology and cancer immunotherapy can be described by immune surveillance,
immune editing, and immune tolerance. A rapid increase in understanding the mechanistic
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pathways of these principles has led to clinical success in the treatment of cancer. In 2001, Robert
Schreiber and Lloyd J Old (considered the father of Tumor Immunology) demonstrated that T
lymphocytes and IFN-γ helped to inhibit the development of spontaneous and carcinogen-
induced tumors in mice genetically deficient in RAG2 [16]. A few tumor cells escaped, however,
from detection and eventually gave rise to tumors. Such selective evasion mechanism in a small
number of tumor cells became known as immunoediting. In fact, the tumor cells that escaped
became less immunogenic than the starting population and were no longer recognized by the
immune system. At the time, the researchers wondered how these tumor cells have learned to
outwit the immune attack.
Immunoediting consists of three well-established and orchestrated following processes called
the 3Es [17]. The first phase is the elimination, in which the immune responses (innate and
adaptive) can recognize and destroy tumors. Normal cells can prevent or inhibit malignant
transformation through the expression of intrinsic tumor suppressors genes such as p16, p53,
BRCA (breast cancer type 1 susceptibility protein), and APC (adenomatous polyposis coli).
Chemical, physical, and biological factors can induce neoplastic transformation and conse-
quently the expression of several tumor antigens, which can be captured, processed, and
presented by dendritic cells and macrophages via MHC/peptides to T naïve cells. Immune
cells such as CD4+, CD8+, NKT, and γδ T cells, as well as NK cells, and the cytokines released
in this environment, such as IFN-y, IFN-α, IFN-β, and perforin, are responsible for tumor cell
killing. The genetic instability and/or immune selection allow the transformed cells to resist to
the immune response, starting the second phase, called equilibrium, in which transformed
cells that had survived to the immune surveillance phase are in dynamic equilibrium (growing
cancer cells = dying cancer cells). When transformed cell variants selected in the second phase
start a clonal growth in an immunologically controlled environment mainly due to the reduction
of cancer immunogenicity followed by the immune exhaustion profile on T cells (PD-1, TIM-3,
Figure 1. Is there an immune response to a malignant tumor? There was a time when the immune system was not
recognized as having a protective role against developing cancer. That was until Burnet named the talent of immune
system to detect tumor cells and destroy them as immune surveillance. Tumor surveillance by the immune system was,
however, difficult to be practically shown.
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LAG-3, and TIGIT), and then, the third phase of immunoediting called escape begins [18].
Classic mediators of immune escape include downregulation of co-stimulatory molecules (B7
molecules), antigen loss by downregulation of MHCmolecules, increased resistance to apoptosis
induction, and cell-mediated cytotoxicity due to the overexpression of antiapoptotic proteins
such as FLIP and BCL-X, mutated Fas and TRAIL [19], expression of T cell inhibitory molecules
such as PD-L1, B7-H3, HLA-G, HLA-E, and B7-x by cancer cells, tumor stromal cells, and APCs
[20]. The presence of CD4 + CD25 + Foxp3 + T regulatory cells, IL-10 secreting T cells, M2
macrophages, immature dendritic cells, and myeloid-derived suppressor cells (MDSC) into the
tumor or draining lymph nodes is decisive to maintain the immunosuppressive environment
[21, 22]. Clearly, without a doubt, the immune system plays a dual role in the multifaceted
interactions between cancer cells and the host.
Based on current immunological findings, the role of the immune system in the recognition
and elimination of transformed cells is beyond any doubt. Numerous studies have investi-
gated the immune system in cancer patients undergoing immunosuppression, mainly due to a
decrease of lymphocyte proliferation and cytotoxic activity [2327]. In this circumstance, the
immune system becomes weak, inactive, or inefficient. Currently, immunotherapy includes
several strategies for restoring cancer patients immune system in an attempt to harness and to
destroy cancer cells specifically. This chapter discusses the recent findings on immune check-
point function and the immune monitoring studies in cancer immunotherapy.
2. T cell activation and immune checkpoint blockade
Currently, the pathways that preclude the complete and responsive immune response to
cancer cells are better understood. Since CTLA-4 (cytotoxic T lymphocyte-associated protein
4) has a marked structural homology to CD28, and because it was unknown whether the
antibodies used were agonistic or antagonistic, it was not clear whether CTLA-4 had an
analogous function as a secondary co-stimulatory agent [28] or an opposing role as a damp-
ener of T cell activation [29, 30]. Only the data from CTLA-4 knockout animals definitively
revealed the inhibitory function of CTLA-4 [31, 32].
Cancer immunotherapy has been declared the breakthrough of the year, in 2013. The ecstasy is
fundamentally grounded on the clinical success of antibodies that modulate immune check-
points mainly by targeting CTLA-4 and PD-1 (programmed cell death protein 1). Immune
responses are tightly regulated by a remarkable system with checkpoints that control either
positively or negatively the magnitude of the immune response. Several immune checkpoint
molecules expressed on T cells can promote activation of naïve T cells (stimulatory checkpoint
pathway) or otherwise inhibit this activation by restraining T cell activation and extension of
the immune response (inhibitory checkpoint pathway), thus regulating the homeostasis, mag-
nitude of inflammation, and tolerance [33]. Positive co-stimulatory molecules on T cells such as
CD28, 4-1BB, OX-40, ICOS, CD2, and CD226 (DNAM-1) allow for T cell activation, prolifera-
tion, and cytokine production. In contrast, negative signals, mediated by LAG-3, CTLA-4, PD-1
and PD-L1, VISTA, B7-H3, CD96, and TIGIT, downregulate T cell activation. These molecules
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are critical to prevent autoimmunity and protect healthy tissues from immune activation.
Finally, signals provided by pro-inflammatory cytokines mainly IL-12, IL-21, and type I inter-
ferons (IFN-α/β) are necessary for T cell response [34]. Blocking CTLA-4 and PD-1 using
monoclonal antibodies represents the innovative concept in cancer therapy owing to (a) these
molecules entirely ignore the tumor cellsthey rely solely on the immune system; (b) they are
not used to activate the immune system against a particular cancer but to neutralize inhibitory
molecules that block a positive antitumor T cell response [35].
The immune system capacity to detect and destroy abnormal cells may prevent the develop-
ment of many cancers. Cancer cells arise from normal cells, driven by mutations that lift brakes
on cell proliferation. As an evolutionary process, tumor cells appropriate regulatory immune
checkpoints to evade elimination. To keep growing, tumor cells take advantage from a sophis-
ticated and dynamic bionetwork called the immune microenvironment. The microenviron-
ment, in addition to tumor cells and infiltrating immune cells, contains epithelial cells,
lymphatic and vascular vessels, cytokines, and chemokines [36]. Targeting the microenviron-
ment for more efficient cancer immunotherapy in solid cancer has been a research objective in
the last decade.
3. Monoclonal antibodies and novel checkpoint inhibitors in cancer
immunotherapy
Monoclonal antibodies have had a considerable impact on the care of patients with cancer in the
last 30 years. The initial report introducing the monoclonal antibody technology (hybridoma
technique) arose from an article published by Köhler and Milstein in 1975, which caused a
tremendous impact on laboratory research [3739]. Sometime later, Kohler and Milstein won
the Nobel Prize in Physiology or Medicine in 1984 awarded jointly to Niels K. Jerne. From then
on, the new monoclonal antibodies aimed at cancer cell proteins such as CD20 (Rituximab,
Ocrelizumab, Veltuzumab, Ofatumumab, and Obinutuzumab), HER-2 (Trastuzumab and
Pertuzumab), EGFR (Cetuximab and Panitumumab), VEGF (Bevacizumab and Ramucirumab),
GD2 ganglioside (Dinutuximab) or the immune cell surface inhibitors, PD-1 (Nivolumab,
Pembrolizumab, and Pidilizumab), CTLA-4 (Ipilimumab and Tremelimumab), and PD-L1
(Atezolizumab, Avelumab, and Durvalumab). More effective immune responses can be
achieved by modifying those monoclonal antibodies when they have failed, mainly due to the
heterogeneity of epitope expression, the delivery to tumor cells, and antigenic modulation [40].
Several monoclonal antibodies have been conjugated to cytotoxic agents (mAb drug conjugates
ADCs). Some examples of ADCs include Ado-trastuzumab (anti-HER2 conjugated with
emtansine), Gentuzumab ozogamicin (anti-CD33 conjugated with calicheamicin), Brentuximab
vedotin (anti-CD30 conjugated with vedotin), immunotoxins (Moxetumomab pasudotox,
Denileukin diftitox, DT2219, Resimmune, and SL-401), and radionuclides (131I-tositumomab
and Y-ibritumomab) [41].
Presently, several efforts are being made to design effective combinations of immunotherapeu-
tic mAbs and new agents that target particular pathways and to reach synergistic effects in the
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Molecule Expression status Function Cognate
ligand
Mechanism of
action
Tested in (Cancer
types)
Blocking
antibodies
CTLA-4
(CD152)
Upon activation of
naïve T cells (CD4+
and CD8+);
Constitutively
expressed on
suppressive T
regulatory cells
(CD4+Foxp3+ T
regs; dendritic cells,
monocytes,
macrophages and B
cells
Critical for
initial
activation
of T cells in
secondary
lymphoid
organs.
Effector
function,
cell
growth,
survival
and
memory
CD80
(B7-1)
CD86
(B7-2)
Outcompeting CD28
and by recruiting
phosphatases to the
cytoplasmic domain
Advanced and
Metastatic
melanoma
Ipilimumab
and
Tremelimumab
PD-1
(CD279)
Inducible on naïve T
cells upon
activation;
Constitutively
expressed on T regs;
monocytes,
macrophages, and B
cells
Critical in
regulating
peripheral
T cells
tolerance.
Effector
function,
cell
growth,
survival
and
memory
PD-L1
PD-L2
Reduces the signal
downstream of TCR
stimulation leading
to a decreased
activation and
cytokine production;
Induce genes that
reduce T cell
proliferation;
decrease anti-
apoptotic proteins
and increase pro
apoptotic
Advanced
melanoma,
metastatic
melanoma,
Prostate,
Colorectal, Non
small cell lung
cancer (NSCLC),
Renal cell
carcinoma (RCC)
Nivolumab and
Pembrolizumab
TIM-3 Dysfunctional CD8+
tumor-infiltrating
lymphocytes (TILs)
also referred to as T
cell exhaustion,
intra-tumor Treg
NK cells,
monocytes,
macrophages and
dendritic cells
Effector
function,
cell
growth,
survival
and
memory
Galectin-9
Ceacam1
HMGB1
PtdSer
Causes negative
signals on T cells
resulting in
apoptosis of Th1 and
CD8+ cells
Tested in solid
tumors and
leukemia
TRS-022,
LY3321367 and
MBG453
LAG-3
(CD223)
T cells, NK cells, B
cells, monocytes,
macrophages,
endothelial cells and
dendritic cells
Also, expressed on
cancer cells
Effector
function,
cell
growth,
survival
and
memory
MHCII
(Higher
affinity
than CD4)
Homologue of CD4+
Negative regulatory
function on T cells;
Mediate a profile of
exhaustion in
combination with
PD-1 and TIM-3 on
CD8+ T cells
Tested in
Advanced renal
cell carcinoma
IMP321
BMS-986016
MK-4280
GSK 2831781
LAG525
TIGIT T cells and NK cells Cell
growth and
effector
function
Interacts
with
members
of
Poliovirus
receptors
family
(PVR)
Acts as a functional
ligand inducing a
tolerogenic
phenotype in
dendritic cells,
resulting in elevated
IL-10 and reduced
IL-12. A regulatory
Locally advanced
or Metastatic solid
tumors
OMP313M32
COM701
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Molecule Expression status Function Cognate
ligand
Mechanism of
action
Tested in (Cancer
types)
Blocking
antibodies
DNAM-1
(CD226)
CD96
PVRL 2
(CD112)
PVR
(CD155)
Other
nectins
role of TIGIT in
modulating the
signaling pathway,
which facilitates
M2-polarization,
a class of
immunosuppressive
tumor associated
macrophages that
arise in response to
Th2 cytokines;
Like PD-1, LAG-3
and TIM-3 can be
expressed by
exhausted CD8+ T
cells
BTLA
(CD272)
Dendritic cells,
monocytes,
macrophages, T cells
(Th1) and B cells
Effector
function,
cell
growth,
survival
and
memory
HVEM Display T cell
inhibition
- -
Data taken from: [20, 22, 3033, 35, 47, 50, 7678, 8994, 100, 107, 109, 110, 112, 114, 116, 118, 124, 127, 130, 137, 145].
Table 1. Targeting potential co-inhibitory molecules which may contribute to improve the immune checkpoint blockade
immunotherapy.
Molecule Expression status Function Receptor Mechanism of action Tested in
(Cancer
types)
Blocking
antibodies
PD-L1 NK cells, endothelial
cells, stromal cells,
epithelial cells and B
cells
Regulates the
development,
maintenance
and functions
of T cells
PD-1 PD-L1/PD-1 on T cells
provides a signal that
prevents TCR-mediated
activation of IL-
2 production and T cell
proliferation. The pathway
involves inhibition
of ZAP70 phosphorylation
and its association
with CD3ζ;
PD-L1/PD-1
attenuates PKC-
θ activation loop
phosphorylation necessary
for the activation of
transcription factors NF-
κB and AP-1, and for
production of IL-2;
PD-L1/PD-1 also
Bladder,
nonsmall
cell lung
cancer,
melanoma,
breast,
ovarian
and
pancreas
Atezolumab;
Avelumab;
Durvalumab
Immune Checkpoint Blockade and Immune Monitoring
http://dx.doi.org/10.5772/intechopen.74688
37
Molecule Expression status Function Receptor Mechanism of action Tested in
(Cancer
types)
Blocking
antibodies
contributes to ligand-
induced TCR down-
regulation during antigen
presentation to naive T
cells
PD-L2 Initially believed to
be restricted to
macrophages and
dendritic cells;
PD-L2 expression
can be induced on a
wide variety of other
immune cells and
nonimmune cells
depending on
microenvironmental
stimuli
Regulates the
development,
maintenance
and functions
of T cells
PD-1 The same effect as above Melanoma,
Renal cell
carcinoma,
non-small
lung cancer
cell,
bladder
and head
and neck
AMP-224
CA-170
B7-H3
(CD276)
Initially was
believed to co-
stimulate the
immune response,
but recent studies
have shown that it
has a co-inhibitory
role on T-cells,
contributing to
tumor cell immune
evasion;
It has been found to
be inducible on T
cells, NK cells, and
APCs;
Broadly expressed
on osteoblasts,
fibroblasts, and
epithelial cells, as
well as in liver, lung,
bladder, testis,
prostate, breast,
placenta, and
lymphoid organs.
Regulates the
development,
maintenance
and functions
of T cells;
Also, this
molecule
influences
cancer
development
and
progression
beyond the
immune
regulatory
roles
TLT-2
receptor on
activated T
cells
It is a member of the B7
family
Melanoma,
Renal cell
carcinoma,
non-small
lung cancer
cell,
bladder
and head
and neck,
prostate,
breast,
MGD009
B7-H4 mRNA is largely
expressed in the
peripheral tissues;
Protein expression is
restricted to
activated B cells, T
cells, and
monocytes.
Regulates the
development,
maintenance
and functions
of T cells;
Also, this
molecule
influences
cancer
development
and
To date, the
cognate
receptor of
B7-H4 on
activated T
cells
remains
unclear,
although
BTLA has
been
It is a member of the B7
family
Nonsmall
cell lung
cancer,
ovarian
cancer,
prostate
cancer,
breast
cancer, and
renal
cancer
-
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Molecule Expression status Function Receptor Mechanism of action Tested in
(Cancer
types)
Blocking
antibodies
progression
beyond the
immune
regulatory
roles
reported as
a possible
receptor.
Galectin-
9
Cancer cells and
MDSC
Regulates the
development,
maintenance
and functions
of T cells;
Also, this
molecule
influences
cancer
development
and
progression
beyond the
immune
regulatory
roles
Loss
of galectin-
9
expression
is closely
associated
with
metastatic
progression
A family of beta-
galactosidase-binding
proteins implicated in
modulating cell-cell and
cell-matrix interactions.
Several
cancer cells
-
Data taken from: [20, 22, 3033, 35, 47, 50, 7678, 8994, 100, 107, 109, 110, 112, 114, 116, 118, 124, 127, 130, 137, 145].
Table 2. Targeting cancer ligands which may contribute to improve the immune checkpoint blockade immunotherapy.
Molecule Expression status Function Cognate
ligand
Mechanism of action Tested in
(Cancer
types)
Agonist
antibodies
CD28 T cells Priming,
survival, cell
growth and
memory
CD80
(B7-1)
CD86
(B7-2)
ICOS-L
(human)
Provide co-
stimulatory signals
required for T cell
activation and
survival. In addition to
the T-cell receptor
(TCR) can provide a
potent signal for the
production of
various interleukin
such IL-2, IL-4, IL-6,
IL-13 and IFN-y
Solid
tumors
Theralizumab
(TGN1412)
CD27 T cells, NK cells and B
cells
Priming,
survival, cell
growth,
differentiation
and memory
CD70 Transduces signals
that promote the
activation of NF-κB
and MAPK8/JNK
Glioma IMA950
ICOS
(CD278)
Is not constitutively
expressed on resting T
Priming,
survival, cell
ICOSL Induce the recruitment
of
Advanced
solid tumors
JTX-2011
GSK3359609IV
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Molecule Expression status Function Cognate
ligand
Mechanism of action Tested in
(Cancer
types)
Agonist
antibodies
cells; Rapidly induced
following TCR cross-
linking and/or CD28
co-stimulation on
T cells and NK cells
growth,
differentiation
and memory
phosphatidylinositol
3-kinase (PI3K)
culminating in the
activation of Akt;
Promotes the
recruitment of p50α
and p85α regulatory
subunits of PI3K, in
conjunction with
recruitment of the
p110δ catalytic subunit
4-1BB
(CD137)
Barely expressed
levels on naïve T cells;
Expressed by
activated T cells, but
to a larger extent on
CD8 than on CD4 T
cells.
Survival, cell
growth,
differentiation
and memory
4-1BBL
(CD137L)
A member of TNF
receptor family;
Delivers
polyubiquitination
signals via TNFR;
inhibits apoptosis,
enhances proliferation
and effector functions;
Alternative NF-κB
activation
Lymphomas PF-05082566
OX40
(CD134)
Expressed on
activated CD4, T regs
and CD8 T cells as
well as in a number of
other lymphoid and
non-lymphoid cells;
Low expression in
naïve effector T cells,
but rapidly
upregulated upon
TCR ligation;
Additionally,
suppresses the
differentiation and
activity of Treg
Survival, cell
growth,
differentiation
and memory;
OX40L Binds to TRAF2, 3 and
5 as well as PI3K;
TRAF2 is required for
survival via NF-κB
and memory cell
generation whereas
TRAF5 seems to have
a modulatory role (as
knockouts have higher
levels of cytokines and
are more susceptible to
Th2-meditated
inflammation;
Appears to be more
potent costimulator of
CD4+ T cells (both Teff
and Treg) than for CD8
+ T cells
Advanced
solid tumors
PF-04518600
MEDI0562
MOXR0916
GITR Expressed in several
cells and tissues
including B cells, T
lymphocytes, NK cells
and antigen-
presenting cells
(APC);
It is upregulated by
responder T cells
(CD4+CD25 T cells or
CD8+CD25 T cells)
Cell growth,
differentiation
and effector
function
GITRL It is a member of the
TNFR superfamily;
GITR signaling is
mediated through the
activation of NF-kB
and members of the
MAPK pathway,
including ERK, p38
and Jnk;
Up regulation of Bcl-
XL expression on
CD8+
Advanced
solid tumors
MEDI1873
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inhibition of tumor growth and development. After plenty of clinical trials and preclinical
models, it is clear now that several inhibitory receptors may need to be blocked so that full T
cell activation and antitumor immunity can be achieved. Blocking some T cell inhibitory
receptors such as TIM-3 (T cell immunoglobulin mucin domain 3), LAG-3 (lymphocyte-
activation gene 3), TIGIT (T cell immunoglobulin and ITIM domain), BTLA (B and T lympho-
cyte attenuator), VISTA (immunoglobulin suppressor of T cell activation), B7-H3, and B7-H4
has emerged as new target for immune checkpoint blockade strategies (Tables 1 and 2). In
contrast, inducing T cell activation by mAbs directed to co-stimulatory molecules such as
CD27, CD28, ICOS, OX-40, 4-1BB, and GITR has been successfully used as a cancer immuno-
therapy strategy against several types of cancer (Table 3) [33, 4249].
4. Checkpoint blockade and neoantigens
The conventional treatment of patients with several cancer types involves in most cases,
surgery, radiation, and chemotherapy. There is a crucial need to develop new therapies for
cancer treatment. Some strategies for cancer immunotherapy including cytokines, signal trans-
duction inhibitors, oncolytic viruses, bispecific antibodies, monoclonal antibodies, dendritic
cells, engineered T cells, drug conjugates, radioimmunotherapy, angiogenesis inhibitors, and
therapy with targeted toxins are currently increasing the perspectives of treating cancer
patients [50]. Nevertheless, despite the recent achievements of these therapies, not every
patient responds to immunotherapy and even the responders often experience toxic effects
[51]. Moreover, there is a rising need to identify potential biomarkers, especially in immune
cells, which could predict whether the cancer patient will respond or not to particular immu-
notherapy, such as immune checkpoint blockade, for example. Also, we need to improve our
knowledge of the fundamental mechanisms and the elegant interface between the immune
system and cancer. For example, dacarbazine has for decades been considered the gold stan-
dard for the treatment of metastatic melanoma. Immunotherapy, however, has extended the
list of options available for the treatment of metastatic melanoma, and its success has been
Molecule Expression status Function Cognate
ligand
Mechanism of action Tested in
(Cancer
types)
Agonist
antibodies
TNFRSF25
(DR3, Apo-
3, LARD,
TRAMP)
Expressed almost
exclusively by
lymphocytes (CD4+,
CD8+, NK and NKT)
Survival,
proliferation
and effector
functions
TL1A The most recently
identified TNF
member;
Transduces signals
that promote the
activation of NF-κB
Not tested
yet
-
Data taken from: [20, 22, 3033, 35, 47, 50, 7678, 8994, 100, 107, 109, 110, 112, 114, 116, 118, 124, 127, 130, 137, 145].
Table 3. Targeting potential co-stimulatory molecules which may contribute to improve the immune checkpoint
blockade immunotherapy.
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supported by studies using immune checkpoint blockade, as with anti-CTLA-4 and anti-PD-1
[52]. Currently, the factors that preclude a completely effective immune response to cancer are
better characterized. Poor immunogenicity is found in several tumors, which can be explained
due to the lack of co-stimulatory factors that provide signals to fully activate T cells, mainly
CD28 molecules [53]. Inhibitory molecules that repress T cell activation can also be present in
the tumor microenvironment. The idea of immune checkpoint blockade and consequently the
renaissance of cancer immunotherapy emerged when James Allisons group questioned why T
cells were not being able to attack cancer cells effectively. Allison decided to look at a biological
molecule called CTLA-4. The first evidence exhibiting the potential effect of anti-CTLA-4 arose
from an article published by his group in 1996. In this article [54], the authors showed that the
injection of a blocking CTLA-4 agent in tumor-bearing mice led to the rejection of pre-
established tumors, including the rejection to the second exposure of tumor cells, when com-
pared with naïve controls. The sequence of experiments published in this paper paved the
route to a new perception in cancer immunotherapythe immune checkpoint blockade [55].
Bristol Myers Squibb (BMS) sponsored the clinical trials with the anti-CTLA-4 antibody under
the name Yervoy. In 2010, the results of the first phase-III clinical trial with Ipilimumab were
published in the New England Journal of Medicine [56]. This paper provided evidence that
Ipilimumab can significantly prolong the lives of patients with metastatic melanoma. A subset
of patients under treatment exhibited permanent beneficial effects, and in some cases, their
cancer was apparently cured. Ipilimumab was the first therapy to provide durable remis-
sions in a fraction of patients with metastatic melanoma in 30 years of exhaustive clinical
research to show improved quality-of-life and overall survival (OS) [57]. The outcomes of a
randomized clinical trial in patients with metastatic melanoma without BRAF mutation were
reported by Robert et al. [58]. In this study, the authors compared the benefits of anti-PD-1
(Nivolumab) and dacarbazine therapy. The treatment with anti-PD-1 enhanced the overall
survival, as compared with dacarbazine (objective response rate, 40 vs. 14%), in patients with
advanced melanoma [58]. In a randomized, double-blind clinical trial, the results of the com-
bination of anti-PD-1 (Nivolumab) and anti-CTLA-4 (Ipilimumab), as reported by Postow
et al., achieved a considerably higher objective rate and longer progression-free survival when
compared with Ipilimumab monotherapy as a first-line treatment in patients with advanced
melanoma [59]. It is not new that the dual blockade using anti-CTLA-4 and anti-PD-1
improves antitumor responses by a complementary and distinctive mechanism [52]. The anti-
CTLA-4 therapy acts improving the priming phase, whereas anti-PD-1 acts helping the effector
phase [60]. Using a murine melanoma model, Curran et al. showed that the combination of
anti-CTLA-4 and anti-PD-1 was more than twice as efficient as either therapy alone in gener-
ating an effector immune response against B16 melanomas. In this preclinical study, the
authors showed that the dual immune blockade was able to expand the effector T cell infiltra-
tion and decrease the regulatory T cells and myeloid cell profile [61]. In another preclinical
study, Selby et al. evaluated the dual blockade in murine colon adenocarcinoma model. The
authors concluded that the concurrent therapy with anti-CTLA-4 and anti-PD-1 caused a
synergic effect in the antitumor activity [62].
In the vast majority of tumors, the combination of the presence of cytotoxic lymphocytes, Th1
profile, and mature dendritic cells (DC) restrained at the tertiary lymphoid structures, are
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associated with an excellent clinical outcome [63]. Nonetheless, recent findings show that the
increase of CD8+ T cell infiltration does not always correlate with a good prognosis in cancer,
as it could be seen in Hodgkin lymphoma, diffuse large B cell lymphoma, renal cell carcinoma
(ccRCC), lung metastases from ccRCC, and nonsmall cell lung cancer (NSCLC) in which
different densities of cytotoxic lymphocytes may or may not correlate with good prognosis
[6468]. These effects could be explained due to the expression of several negative immune
checkpoints such as CTLA-4, PD-1, BTLA, TIM-3, LAG-3, VISTA, and TIGIT in infiltrating T
cells or its ligands on tumor cells such as PD-L1, PD-L2, B7-H3, B7-H4 and HVEM that are
fundamental to immune escape in cancer [51]. In fact, the nature of the interaction between the
immune system and the tumor allows for the clinician to predict patients prognosis and
further guide immunotherapeutic strategies. One of the most meaningful challenges to the
triumph of cancer immunotherapy is the relatively small percentage of responding patients.
The leading causes of resistance to cancer immunotherapy, especially to the immune check-
points blockade, could be explained by the failure of the T cells to become fully activated.
Severely immune-compromised patients, low mutational neoantigen rates, inhibitory mole-
cules, and the tumor microenvironment are considered crucial to dampening T cell activity
[69]. Indeed, the resistance could also be induced by immunotherapy. After recognizing the
antigen, the tumor-infiltrating lymphocytes (TILs) become activated, and then they start to
produce IFN-γ. As a result of this activation, the IFN-γ released can promote the expression of
PD-L1 on the tumor cells and increased IDO (indoleamine 2,3 dioxygenase) and CEACAM1
(carcinoembryonic antigen-related cell adhesion molecule 1) [7072].
Starting with the comprehension that cancer is a genetic disease, the design of personalized
molecularly targeted therapies, seems a rational step to endeavor. Resistance to several of these
therapeutic agents such as Vemurafenib, Imatinib, Nilotinib, Erlotinib, and Trastuzumab is the
main issue focused on current cancer research [73]. Transformed cells that may express, for
instance, high levels of BRAF mutations, BCR-ABL, EGFR, and HER2 must be discerned from
nontransformed cells. Through natural selection transformed cells, submitted to molecularly
targeted therapies, have learned to escape from these therapies. Alterations in the drug target,
activation of pro-survival pathways, and ineffective induction of cell death are some examples
[74]. Consequently, there is a critical demand to develop new therapies for cancer treatment.
The role of the immune system and its importance in conferring protection against
transformed cells have been extensively discussed in this book. As the results from the last 10
years attest, cancer immunotherapy is the best strategy to restore the activity of the immune
system and unleash its potential to destroy cancer cells in cancer patients. The absence of an
immunocompetent system revealed the increase in the susceptibility to carcinogens induced in
spontaneous cancer [75]. The genetic landscape of the antigens that allow the immune system
to discriminate between cancer cells from nontransformed cells remains unclear. Not all anti-
gens can elicit an effective immune response. A tumor rejection is defined by how satisfactory
an immune response can act against a specific tumor antigen and how this response would
impact on tumor growth [76].
Deep sequencing and DNA libraries have profoundly contributed to cancer immunology and
immunotherapy, mainly by the characterization of neoantigens that arise from tumor-specific
mutations [76]. As cancer cells divide, they accumulate mutations that result in altered or novel
Immune Checkpoint Blockade and Immune Monitoring
http://dx.doi.org/10.5772/intechopen.74688
43
peptide sequences specific to the tumor cell. Distinguished as neoantigens, these tumor-specific
antigens could be the key to developing successful cancer therapies [77]. The exome-based
cancer is, indeed, a crucial approach to determine the T cell reactivity against cancer
neoantigens [78]. Preclinical models conducted by Castle et al. and Matsushita et al. provided
the original evidence for the cancer exome-based method that could be used to identify
neoantigens and interrogate about the T cell reactivity [79, 80]. One of the reasons why the
immune checkpoint blockade, especially by anti-CTLA-4 and anti-PD1, successfully works on
melanoma and lung cancer patients is the potential formation of a neoantigen repertoire [81].
Melanoma and lung cancer cells have a mutational rate above 10 somatic mutations per
megabase (Mb) of encoding DNA, unlike astrocytoma, thyroid, medulloblastoma, neuroblas-
toma, glioblastoma, myeloma, ovary, thyroid, pancreas, and prostate cancers, which occasion-
ally have one mutation per megabase [82]. That could explain why the effectiveness of the
immune checkpoint blockade is not impressive in those tumors that have few somatic muta-
tions and consequently a poor neoantigen repertoire. Such evidence together with assumptions
about the tumor microenvironment, immune privilege, and the expression of negative immune
checkpoints lead to an insufficient T cell activity [83, 84] and consequently cancer progression.
Several groups are trying to develop novel approaches so that the effect of the immune
checkpoint blockade could be augmented in patients with few somatic mutations. To this
end, the researchers are focusing their attention on the mechanisms involved in the antitumor
response [85]. Preclinical models suggest that an effective antitumor response is obtained
when Ipilimumab and Nivolumab induce lymphocyte responses to neoantigens expressed on
the individual tumor [86]. If so, a therapeutic approach could be the combination of the
immune checkpoint blockade with peptide vaccines. Since the majority of mutations are
patient specific, this new approach could lead the way favoring personalized immunotherapy,
combining immune checkpoint blockade with cancer vaccines containing a cocktail of peptides
corresponding to neoantigens known to be expressed in a given patients tumor cells.
In prostate cancer and gliomas, for example, the challenge for developing effective immuno-
therapy is discouraging. Although prostate cancer had the first adult solid tumor-approved
vaccine (Sipuleucel-T), which prolongs survival, it was difficult to go beyond that [87]. High-
grade gliomas such as DIPG (Diffuse Intrinsic Pontine Glioma) are destructive and incurable
cancers, representing the main cause of pediatric brain tumor death. Growing diffusely
in the ventral pons, DIPG causes disabling neurologic symptoms that gradually abolish the
coordination of the face, pharynx, and body. Unfortunately, surgical resection is not a feasi-
ble option, radiation therapy results in just temporary stabilization of symptoms, and several
chemotherapy trials developed for adult glioma have not been successful to date [88].
In both scenarios, the challenges that may account for this negative outcome could be (a)
there are no immune-related biomarkers that can monitor efficacy in easily accessible tissues;
(b) immunologic changes within the peripheral blood have been relatively unhelpful; (c)
there is a disease stage; d) the immunotherapy efficacy may be therapy-specific (i.e., immune
checkpoint therapies are more effective in cancers with high mutation rate, whereas vaccines
can be more effective early in tumor progression [89]. As a basis for future research in cancer
immunotherapy, immunological pathways in response to monotherapy versus combin-
ation therapy need to be assessed in the context of clinical outcome. Novel predictive and
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prognostic biomarkers have been identified for immune monitoring and clinical correlation
in several types of cancer [9092].
5. Cancer immune monitoring
Immune monitoring studies have supported the hypothesis that combining immunotherapy
and standard treatment or their use as monotherapy can benefit patients developing different
types of cancer. Analyzes involved ligands, infiltration quality, co-stimulatory/inhibitory pro-
file, and microenvironment. Several assays such as whole exome sequencing (WES), protein
array, flow/mass cytometry (CyTOF), multicolor immunohistochemistry (IHC), Multiplexed
Ion Beam Imaging (MIBI), Systematic evolution of ligands by exponential enrichment (SELEX),
epigenetic modification, and B/T cell receptor repertoire sequencing have been used to pursue
potential biomarkers and contribute for the future of cancer immunotherapy [9396]. Also,
these studies have the potential to elucidate immunological mechanisms of antitumor
responses, monitor disease progression, evaluate the therapeutic effect, identify candidates
for immunotherapy, and serve as prognostic markers of clinical outcome. As discussed above,
neoantigens expressed on cancer cells can elicit cellular and humoral immune responses, and
they also can be identified to develop immunotherapies [97]. Patient serum and tissue samples
can be analyzed to determine candidate tumor-associated neoantigens or genes that evoke
cellular and humoral immune responses in cancer patient [98]. Since fresh tumor samples from
cancer patients are not always possible to obtain, several clinical studies are undertaken on
peripheral blood samples. The successfulness of anti-CTLA-4 and anti-PD-1 in the clinic has
stimulated further studies on other molecules that can be targeted. There are several known
checkpoint molecules, and their evaluation has progressed to clinical trials. Immunophe-
notyping studies using the approaches quoted above, examine for instance, the activation or
exhaustion of the T cell markers (CD28, CD27, ICOS, OX40, GITR, 4-1BB, PD-1, CTLA-4, LAG-
3, TIGIT, TIM-3, BTLA, and VISTA) and the tumor microenvironment ligands (PD-L1, PD-L2,
ICOSL, OX-40L, 4-1BBL, Galectin, B7H3, and B7H4). T cell populations including but not
limited to CD4 cells, CD8 cells, NK cells, and their subpopulations such as activated T cells,
MDSCs, and Tregs have been analyzed in several immune monitoring studies [99103]. Serum
cytokines, chemokines, and angiogenic factors have also been investigated by ELISA,
ELISPOT, or other relevant multiplex-based protein assay methods [104, 105]. By questioning
the efficacy and even the possible failure, the potential of using immune monitoring studies in
cancer prognosis, prediction of treatment efficacy, immune tolerance, and disease progression
have contributed to the improvement of the immune-related response criteria (irRC) [106].
Currently, immune checkpoint blockade therapies represent the breakthrough in cancer ther-
apy and have led to robust antitumor responses and clinical benefit in a large number of
patients with cancer, but, despite the outstanding achievement of clinical applications of the
checkpoint blockade, the efficacy of these therapies differ critically across individual patients
and among different tumor types [107, 108]. There is an urgent need to find potential bio-
markers that could predict whether cancer patients would respond to the immune checkpoint
blockade [109].
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Fan et al. using Ipilimumab in a cohort of patients with bladder cancer showed the ICOS
molecule (Inducible T cell co-stimulator) to be selectively upregulated in intratumor CD8+
and CD4+ T effector cells [110]. This particular clinical trial indicated the ICOS/ICOSL pathway
as relevant for antitumor immune responses in bladder cancer patients under Ipilimumab
treatment. Liakou et al. showed that Ipilimumab therapy led to an increase in IFN-y secretion
by T cells [111]. It is well-established that melanoma cells are sensitive to IFN-y and quite often
some cells containing defective IFN-y signaling genes may be resistant to IFN-y mediated
growth inhibition and apoptosis. In order to investigate the reasons determining responders
or nonresponders to Ipilimumab therapy, Gao et al. evaluated from whole exome sequencing
data the genomic alterations in the family genes of IFN-y pathways in melanoma tumors [112].
The authors encountered significantly more somatic mutations, including copy-number alter-
ations (CNAs) and single-nucleotide variants (SNVs) in nonresponders. Since their results
suggested that CNAs in genes of the IFN-y pathways in melanoma patients could predict
initial resistance to Ipilimumab, the authors also evaluated data on a total of 367 patients with
metastatic melanoma in the TCGA (The Cancer Genome Atlas) database. About 36% of
patients had CNAs in the IFN-y pathway genes and had significantly shorter overall survival
when compared with the wild-type tumor genes. In order to explain the acquired resistance to
PD-1 blockade (Pembrolizumab) treatment, Zaretsky et al. compared melanoma tissues from
the baseline with the tumors that had relapsed months to years. As a result, the authors found
new JAK1/2 loss-of-function mutations and truncating mutations in the beta-2 microglobulin
(B2M) gene. These two studies are closely related to the melanoma development, progression,
and primary resistance to anti-CTLA-4 and anti PD-1 [113, 114].
Immune checkpoint blockade seems to be a promising approach for patients with orphan
types of cancer like squamous cell carcinoma (SCC). This type of cancer is rare and is caused
by Human Papillomavirus (HPV) infection. Until now, there is no consensus treatment for the
metastatic form. Morris et al. evaluated tissues from patients who received at least one dose of
Nivolumab. As a result, the authors found an objective response in 24% of patients with
metastatic SCC. Immunohistochemistry and flow cytometry of baseline biopsies showed a link
between the therapy responses and the presence of an activated inflammatory profile in the
tumor. Tumors from the responders had more activated effector T cells at baseline than non-
responders. The authors also showed a high expression of PD-1/PD-L1 and higher co-
expression of inhibitory molecules such as LAG-3 and TIM-3 in baseline tissues among
responders than in nonresponders [115], indicating a previous activation profile in those cells
before the treatment. These results were consistent with other solid tumors such as melanoma
[56]. The expression of immune molecules in pretreatment biopsies has been described to
correlate with response rates in patients with melanoma and other types of cancer, but a
fundamental class of biomarkers has not been identified. It seems that PD-1/PD-L1 and inhib-
itory molecules may serve as an indirect biomarker of acquired immune resistance in response
to tumor antigen-specific T cell infiltration [116]. Gao et al. identified additional immune-
inhibitory paths in the prostate tumor microenvironment in patients untreated and treated
with Ipilimumab. Under the Ipilimumab therapy, there was an increase in immune cells
infiltration, including macrophages expressing PD-L1 and VISTA both acting as suppressors
of T cell function. Their data advocated that VISTA could represent another inhibitory
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mediator after immune checkpoint blockade therapy [117]. Genomic and cellular tools to
determine several immune signatures in longitudinal biopsies collected at multiple time points
during anti-CTLA-4 followed by an anti-PD-1 blockade of melanoma progression were used
by Chen et al. [109]. At the baseline, there was no change in any of the measured biomarkers
(CD45RO, CD20, CD57, CD68, Foxp3, Granzyme B, PD-1, LAG-3, CD14, CD33, CD163, and
CD206), comparing responders and nonresponders to the CTLA-4 blockade. During the treat-
ment, however, there was a significantly higher density of CD8+ T cells in responders than in
nonresponders. Furthermore, a higher expression of CD45RO, CD20, CD57, Foxp3, and
Granzyme B was observed in responders versus nonresponders in the CTLA-4 blockade arm.
Together, these data are relevant in the attempt to identify biomarkers of response and resistance
to the immune checkpoint blockade while offering a mechanistic understanding of PD-1 block-
ade as associated to enhanced cytotoxic activity, antigen processing, and IFN-y pathway [109].
Anagnostou et al. performed a comprehensive study using a genome-wide sequence of
protein-coding genes and T cell receptor clonotype analysis followed by functional assays of
autologous T cell activation of nonsmall cell lung cancer in patients that demonstrated initial
response and in those patients who experienced checkpoint blockade resistance (anti-CTLA/-
anti-PD-1). The authors found a relationship between the acquired resistance and the loss of
mutations encoding putative tumor-specific neoantigens. In the tumor samples analyzed at the
time of acquired resistance, the authors also found that the majority of eliminated mutations
were in genes typically expressed at high levels in lung cancer, which encoded neoantigens that
were predicted to either confer high-affinity MHC binding or affect TCR contact residues [118].
TIM-3 is a co-inhibitory immune checkpoint receptor that is highly expressed in dysfunctional
CD8+ tumor-infiltrating lymphocytes (TILs) also referred to as T cell exhaustion, intra-tumor
Treg cells, monocytes, macrophages, and dendritic cells [119]. It is characterized as a type I
transmembrane protein that was originally described in an EAE model (autoimmune enceph-
alomyelitis). Monney et al., in an attempt to identify novel cell surface molecules that would
label IFN-y producing Th1 and CD8+ stimulated naïve T cells, found the expression of TIM-3
in these cells. Furthermore, subsequent studies showed that anti-TIM-3 antibodies exacerbated
EAE [120]. Galectin-9 (C-type lectin galectin-9), Ceacam 1 (carcinoembryonic antigen cell
adhesion molecule 1), HMGB1 (high-mobility group box 1), and PtdSer (phosphatidylserine)
have been identified as four TIM-3 ligands [121]. Interaction with TIM-3 caused negative
signals on T cells resulting in apoptosis of Th1 and CD8+ cells [122].
High levels of TIM-3 on CD8+ have been correlated with poor prognosis in tumor progression
[123]. Exhausted T cells were associated with PD-1+ single positive CD8+ cells [56]. In some
types of cancer as lung, melanoma, and renal cancer, resistance to these therapies has gradu-
ally been observed [124127]. To elucidate the mechanisms of adaptive resistance, Koyama
et al. analyzed the tumor microenvironment in the context of anti-PD-1 therapy in two immu-
nocompetent mouse models of lung adenocarcinoma. In the tumor progression, following
response to anti-PD-1, the authors observed upregulation of TIM-3. According to the mouse
model, TIM-3 upregulation was time dependent in TILs expressing PD-1. TIM-3 blockade
using anti-TIM-3 overcame the acquired resistance to the PD-1 blockade. Furthermore, the
same scenario could be observed in humans. Patients who developed adaptive resistance to
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anti-PD-1 therapy also showed a comparable TIM-3 upregulation [119]. In patients with
metastatic melanoma, Fourcade et al. found approximately 30% of NY-ESO-1specific CD8+
T cells that expressed TIM-3 [128]. Gao et al. analyzed patients with nonsmall cell lung cancer
(NSCLC), and approximately one-third of CD8+ tumor-infiltrating T lymphocytes (TIL)
expressed TIM-3 [129]. Also, Yang et al. analyzed patients with follicular B cell non-Hodgkin
lymphoma, and approximately one-third of lymph node CD4+ T and CD8+ T cells expressed
TIM-3 [130]. In these three different types of cancers, TIM-3 positive T cells co-expressed PD-1
and exhibited defects in the proliferation of effector cells and cytokine production. In fact, TIM-
3 labels dysfunctional T cells in multiple cancer types both in experimental models and in
humans. Anti-TIM-3 antibodies have shown good results as monotherapy in some preclinical
cancer models and when used in combination with anti-PD-1 antibodies [131134]. Since TIM-
3 expression has been shown to regulate Th1 and Tc1 responses negatively, Th17/T regulatory
cells, innate cell activation, and T cell exhaustion, there is rational evidence for targeting TIM-3
[135]. Recently, Gefen et al. isolated an oligonucleotide aptamer ligand that blocked the inter-
action between TIM-3 with Galectin-9 with a high-affinity and specificity in T cells. The authors
demonstrated in vitro, a reduced cell death followed by enhanced survival, proliferation, and
cytokine secretion. In in vivo experiments, the aptamer postponed tumor development as
monotherapy and synergized with anti-PD-1 in prolonging the survival of the tumor-bearing
mice. Together, these results indicate that TIM-3 signaling exerts a secondary effect in keeping
T cell immune responses in check [136].
LAG-3 (Lymphocyte-activation gene) is a reliable cancer immunotherapeutic target like TIM-3,
due to its negative regulatory function on T cells and its ability to mediate a profile of
exhaustion in combination with PD-1 [137]. LAG-3 is a type I membrane protein highly
homologous in structure to CD4, described for the first time in 1990 as a novel protein
identified on activated NK and T cells [138]. The structural motifs in CD4 and LAG-3 are
highly conserved, but LAG-3 can bind to MHC class II molecules with higher affinity than
CD4 [139]. As TIM-3 is a marker of IFN-producing Th1 cells, LAG-3 is a marker of IL-10
producing T regulatory cells in both mice and humans [140]. The first evidence in vitro on the
role of LAG-3 inhibiting T cells was shown by Huard et al., when the authors by blocking
LAG-3 increased the proliferation of human T cells [141]. Furthermore, the ectopic expression
of LAG-3 on mouse CD4+ T cells reduced their proliferation [142] significantly. Unlike CTLA-4
knockout (KO) mice, which develop spontaneous lymphoproliferative diseases, mice lacking
LAG-3 do not develop lymphoproliferative disorders. In the absence of LAG-3, however, T
regulatory cells display a reduced activity [143]. Besides the negative regulation on T cell
activation, innate cell activation, and T cell exhaustion, LAG-3 also induces the upregulation
of cell surface receptors such as CD40, CD80, CD83, and CD86 in monocyte-derived dendritic
cells (DCs) [144]. These facts led Quezada et al. to affirm that LAG-3 has a more complex role
in immune homeostasis than just inhibiting T cell activation [145]. LAG-3 has been suggested
to regulate the activity of PD-1 cells, and their co-expression has been shown in malignant
mouse and human tumor cells [146]. Using murine models of B16 melanoma, MC38 colorectal
adenocarcinoma, and Sa1N fibrosarcoma, Woo et al. also showed that the combinations of
anti-LAG-3/anti-PD-1 antibodies inhibited tumor growth and progression besides enhancing
adaptive immune responses in tumor-infiltrating lymphocytes [147].
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TIGIT (T cell immunoreceptor with Ig and ITIM domains) also known as WUCAM is an inhibi-
tory receptor, member of the poliovirus receptor (PVR/nectin family) classified as type 1 trans-
membrane domain, with an intracellular domain containing a canonical receptor tyrosine-based
inhibitory motif (ITIM) and an immunoglobulin tyrosine tail (ITT) [148]. Yu et al [149] discov-
ered TIGIT expressed in regulatory, memory and activated T cells. Currently, we know that
TIGIT is also expressed in T regulatory and NK cells in multiple types of cancer [150]. CD155
and CD122 are TIGIT ligands, expressed in macrophages and dendritic cells [151]. TIGIT is
upregulated in tumor-specific peripheral CD8+ T cells and CD8+ tumor-infiltrating lympho-
cytes (TILs) from patients with metastatic melanoma and TIGIT-expressing CD8+ T cells often
co-express PD-1. In metastatic melanoma, Chauvin et al. showed that TILs from these patients
downregulated the co-stimulatory molecule CD226. It has been shown that CD226 competes
with TIGIT for the same ligand, supporting a TIGIT/CD226 imbalance in metastatic melanoma
[152]. In addition to its role as a lymphocyte receptor, TIGIT acts as a functional ligand
inducing a tolerogenic phenotype in dendritic cells, resulting in elevated IL-10 and reduced
IL-12 [153]. A regulatory role of TIGIT in modulating the signaling pathway, which facilitates
M2-polarization, a class of immunosuppressive tumor-associated macrophages that arise in
response to Th2 cytokines was shown by Chen et al. [154]. The capacity of TIGIT to interfere in
the tumor microenvironment by suppressing the immune response mediated by an increase of
T regulatory activity, recruitment of MDSC, induction of blood vessel formation, cancer-
associated fibroblasts, NK cell inhibition, and CD8+ T cell-mediated tumor killing, priming,
and differentiation, suggest altogether that cancer cells upregulate TIGIT pathway to promote
immunosuppression [151]. TIGIT becomes, therefore, a good candidate for the blockade in
combination with anti-CTLA-4 and anti PD-1 [155161].
VISTA (V-region Immunoglobulin-containing Suppressor of T Cell Activation) was discov-
ered, characterized, and functionally defined as a novel hematopoietically restricted inhibitory
ligand by Noelles group. It is expressed primarily within the hematopoietic compartment
(monocytes, neutrophil, and dendritic cells) with a low expression on CD4+, CD4+ Foxp3+ T
regulatory cells, and CD8+ T cells [162]. VISTA is a type I transmembrane protein, with a single
N-terminal immunoglobulin V domain and sharing structural similarities with PD-1, CD28,
and CTLA-4 [163]. Remarkably, this molecule is at the same time a ligand and can function as a
receptor. Wang et al. evaluated in vitro and in vivo the role of VISTA as a ligand. The authors
conducted a range of experiments using VISTA-Ig fusion protein or VISTA expression on
APCs. In both situations, VISTA was able to inhibit CD8+ T and CD4+ T cell proliferation and
cytokine production at the early stage of activation mainly by suppression of CD25, CD44,
CD69, and CD62L markers, IL-2, and IFN-y [164, 165]. In vivo experiments led the authors to
conclude that VISTA expression in tumor cells can overcome protective antitumor immunity.
To achieve this conclusion, mice were immunized with irradiated MCA105 fibrosarcoma
tumor cells that do not express VISTA and were re-challenged with MCA105 overexpressing
VISTA. Cancer cells expressing VISTA showed enhanced tumor growth compared to the
VISTA negative parent MCA105. Furthermore, Lines et al. using VISTA-Ig fusion protein
demonstrated in vitro that VISTA could increase the conversion of naïve CD4+ T into T
regulatory cells in both human and mice [166]. The anti-VISTA monotherapy impaired tumor
growth in several types of cancer (B16OVA melanoma, B16-BL6 melanoma, MB49 bladder
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carcinoma, and PTEN/BRAF inducible melanoma) and altered the cellular composition of the
tumor microenvironment enhancing T cell responses within the tumor by cytotoxic and cyto-
kine production such as IFN-y and TNF-alpha [167].
As a receptor, VISTA molecules on T cells have been shown to regulate their activity nega-
tively. VISTA is a co-inhibitory receptor on CD4+ T cells because it suppresses early CD4+ T cell
expansion in vivo and CD4+ T VISTA/ cells responded more strongly than wild-type (WT)
CD4+ T cells to both polyclonal and antigen-specific stimulation, leading to increased prolifer-
ation and production of cytokines such IFN-γ, TNFα, and IL-17A. The anti-VISTA monot-
herapy impaired tumor growth in several types of cancer (B16OVA melanoma, B16-BL6
melanoma, MB49 bladder carcinoma, and PTEN/BRAF inducible melanoma) and altered the
cellular composition of the tumor microenvironment enhancing T cell responses within the
tumor by cytotoxic and cytokine production such as IFN-y and TNF-alpha [167]. Their results
announced a new role for VISTA molecules, as a regulator of the tumor microenvironment
playing an essential function in regulating protective immunity to cancer.
The exciting development of cancer treatment recently fostered the ambition of the traditional
cancer therapy to increase the median of survival from a few months to definitely announce
victory against cancer. Currently, we have been able to move the median survival a little longer
especially with the approval by the FDA of anti-CTLA-4, anti-PD-1, and therapeutic combina-
tions. One must be cautious, however, because currently, only about 30% patients are respon-
ders to immunotherapy. This fact has incited for the search of new molecules, new biomarkers,
and new combinations such as other checkpoint blockers, co-stimulatory molecules agonists,
IDO pathway inhibition, oncolytic viruses, adoptive T cell transfer, T cell engineering, thera-
peutic vaccines, targeted therapy, chemotherapy, and radiotherapy in the attempt to increase
the number of responders and consequently of survivors. There has been much of enthusiasm
on recent news about immunotherapy in the treatment of cancer patients. Int the past year,
checkpoint inhibitors have become an impotant tool for treating certain types of tumor such as
non-small cell lung cancer (NSCLC) and melanoma with an increase in the median survival.
Novel immunotherapeutic approaches are essential to the success in the treatment of different
cancer types.
6. Conclusion
The effectiveness of monoclonal antibodies, especially the immune checkpoint blocking ones,
associated to other cancer therapies and consequently with the improvement of preclinical
studies and the advent of screening techniques, constitutes a unique opportunity to understand
and overcome drug resistance. Not only that but also by profoundly investigating predictive
biomarkers related to the different immunotherapeutic agents. As discussed in this chapter, to
date, there are three types of potential biomarkers that have been studied exhaustively: (a)
Immune infiltrate in the tumor; (b) high mutation profile (neoantigens); and (c) expression
of PD-L1 by tumor cells or tumor cell infiltrates. Data from immune monitoring studies have
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provided a link between immunologic/genomic and proteomic platforms. The main goals of the
immune checkpoint blockade are to either stimulate the T cells to attack cancer cells or to
suspend the suppression of remaining antitumor T cells. The immune monitoring study consists
in analyzing the activity of innate and adaptive cell populations like T cells, B cells, myeloid-
derived suppressor cells (MDSC) and natural killer (NK) cells, which are critical in the immune
response against cancer and may regulate positively or negatively T cell responses. In summary,
this approach may lead to the identification of biomarkers that will predict whether immune
checkpoint blockade (monotherapy or combination) would be sufficient to induce an objective
response.
The most critical cell populations include the total CD4+ T and effector CD4+ T cells, T
regulatory cells, total CD8+ T, naive, T central memory and T effector memory cells; MDSC
(myeloid-derived suppressor cell), and B cells; and M1 and M2 macrophages have recently
being studied in the context of cancer development. A great number of molecules involved in
immune responses against cancer cells have been studied, such as immune checkpoint mole-
cules on T cells, 4-1BB (CD137), CTLA-4, GITR (glucocorticoid-induced TNFR-related protein),
OX-40 (CD134), TIM-3, LAG-3, PD-1, and ICOS (inducible T cell co-stimulator); cytotoxic and
cytokine secreting molecules on NK cells such as 4-1BB, CD69, NKG2A, NKG2C, NKG2D,
NKp30, NKp44, and NKp46; some ligands on tumor cells such as B7H3, B7H4, CD73, CD80,
CD86, CD137, PD-L1, PD-L2, ICOSL, Galectin 9, MIC A/B and OX40; and the expression of
transcription factors such as Bcl-6, Blimp, CD27, CD28, Eomes, Ki-67, ICOS, and c-myc. They
might bring a better understanding of the immune response under immunotherapy and help
us to answer why not every patient responds to immunotherapy. Immunotherapy offers at
least three actions that no other modality of cancer therapy provides: specificity, memory, and
adaptability. We have consistently seen that one of the principal issues of immunotherapy
strategy is the enhanced proportion of responders to the immunotherapeutic agents. Combin-
ing immune checkpoint blockade with other therapies, which overcome the possible failures,
may lead to synergies. That is the reason why the most broadly studied combination of check-
point blockade agents uses the anti-CTLA-4 and anti-PD-1 monoclonal antibodies. However,
a more in-depth understanding on the mechanisms of efficacy and the identification of resis-
tance to checkpoint blockade and their agents are needed. Despite significant progress in the
immune checkpoint blockade, much remains to be done. Inquiries on the responder profile, the
differences between mouse models and results application to clinical studies, the relative
effects on effector, T regulatory and other cells, expressing several immune checkpoints, and
the comprehension regarding the differences between the immune profile in different com-
partments such as in the periphery versus the tumor microenvironment must be addressed.
Clinical samples and immune monitoring approaches obtained at multiple time points during
immune checkpoint blockade would be valuable for exploring the responsiveness and nonres-
ponsiveness profile. Additionally, studies of immune modifications within human cancer cells
and the tumor microenvironment have the potential to establish efficacy and resistance mech-
anisms. In this context, The Cancer Genome Atlas project (TCGA, available at https://cancerge-
nome.nih.gov) has helped to identify some mutations in cancer cells, which increase the
prospect of resistance to immunotherapy. Exciting secret waits to be unveiled.
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